Maxwell Skor
Stock Analyst at Morgan Stanley
(4.53)
# 1,058
Out of 5,119 analysts
268
Total ratings
59.1%
Success rate
14.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintained: Buy | $62 | $34.39 | +80.28% | 100 | Nov 9, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $273 | $256.82 | +6.30% | 36 | Nov 9, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $18 | $7.62 | +136.22% | 2 | Nov 6, 2026 | |
| CYTK Cytokinetics | Rated: Buy | $103 | $53.69 | +91.84% | 22 | Nov 5, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Hold | $20 → $22 | $15.43 | +42.58% | 16 | Nov 4, 2026 | |
| INSM Insmed | Rated: Buy | $213 | $114.41 | +86.18% | 34 | Oct 30, 2026 | |
| ACHV Achieve Life Sciences | Reiterated: Buy | $13 | $6.72 | +93.45% | 2 | Oct 21, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Hold | n/a | $12.25 | - | 1 | Oct 21, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Hold | $60 | $50.07 | +19.83% | 3 | Aug 28, 2026 | |
| ADAG Adagene | Reiterated: Hold | n/a | $2.00 | - | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.61 | - | 9 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $115 → $130 | $71.42 | +82.02% | 4 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $2.37 | +406.33% | 4 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.188 | - | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $7 | $4.31 | +62.41% | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9.5 → $3.55 | $0.563 | n/a | 10 | Nov 20, 2024 |
Pharvaris
Nov 9, 2026
Maintained: Buy
Price Target: $62
Current: $34.39
Upside: +80.28%
Ascendis Pharma
Nov 9, 2026
Maintained: Buy
Price Target: $273
Current: $256.82
Upside: +6.30%
REGENXBIO
Nov 6, 2026
Reiterated: Buy
Price Target: $18
Current: $7.62
Upside: +136.22%
Cytokinetics
Nov 5, 2026
Rated: Buy
Price Target: $103
Current: $53.69
Upside: +91.84%
Ultragenyx Pharmaceutical
Nov 4, 2026
Reiterated: Hold
Price Target: $20 → $22
Current: $15.43
Upside: +42.58%
Insmed
Oct 30, 2026
Rated: Buy
Price Target: $213
Current: $114.41
Upside: +86.18%
Achieve Life Sciences
Oct 21, 2026
Reiterated: Buy
Price Target: $13
Current: $6.72
Upside: +93.45%
4D Molecular Therapeutics
Oct 21, 2026
Reiterated: Hold
Price Target: n/a
Current: $12.25
Upside: -
CRISPR Therapeutics AG
Aug 28, 2026
Reiterated: Hold
Price Target: $60
Current: $50.07
Upside: +19.83%
Adagene
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.00
Upside: -
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.61
Upside: -
Aug 17, 2026
Rated: Buy
Price Target: $115 → $130
Current: $71.42
Upside: +82.02%
Aug 17, 2026
Rated: Buy
Price Target: $12
Current: $2.37
Upside: +406.33%
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.188
Upside: -
Aug 13, 2026
Rated: Hold
Price Target: $6 → $7
Current: $4.31
Upside: +62.41%
Nov 20, 2024
Reiterated: Buy
Price Target: $9.5 → $3.55
Current: $0.563
Upside: n/a